在结直肠癌中,B-Myb 缺乏会增强 bortezomib 诱导的免疫细胞死亡
Yuan-Jian Hui1,2, Ting-Ting Yu3,4, Liu-Gen Li3
1Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Jiefang Road No. 238, Wuhan, 430060, Hubei Province, China.
Scientific reports
|April 2, 2024
概括
在结直肠癌中删除B-Myb通过增加DNA损伤和免疫性来增强Bortezomib (BTZ) 的疗效. 这一策略针对癌细胞,以改善免疫疗法结果.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 免疫治疗是一种免疫疗法.
背景情况:
- B-Myb对于DNA修复和瘤生长至关重要.
- 它在结肠直肠癌 (CRC) 化疗和免疫治疗中的作用尚未得到研究.
- 博尔特佐米布 (BTZ) 是有前途的药物,但在高B-Myb的CRC中无效.
研究的目的:
- 调查B-Myb删除是否可以提高BTZ在CRC中的免疫功效.
- 阐明这种增强潜力的潜在机制.
主要方法:
- 在CRC细胞和瘤携带小鼠中稳定B-Myb敲击.
- 评估细胞亡,细胞循环停止和DNA损伤.
- 对基因表达 (p53通路,HMGB1,HSP90) 和巨细胞两极分化的分析.
主要成果:
- 在体外和体内,B-Myb敲击增加了癌细胞亡和BTZ疗效.
- 在B-Myb缺陷的CRC中,BTZ诱导了更强的DNA损伤和细胞循环停止.
- B-Myb 枯竭通过 HMGB1/HSP90 增强了 BTZ 诱导的免疫性,促进了 M1 巨细胞两极分化.
结论:
- 删除B-Myb促进了免疫性癌细胞死亡,放大了BTZ的免疫功效.
- 向B-Myb是改善结直肠癌BTZ免疫疗法的潜在策略.
关键词:
B-Myb (MYBL2) 是一个类型.生物信息学是一种生物信息学.博尔特佐米布 (BTZ) 是一种药物.造成的DNA损伤是DNA损伤.免疫性死亡 (ICD) 是一种免疫性死亡.巨细胞是什么?巨细胞是什么?更多相关视频
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.7K
11:25Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
Published on: April 1, 2015
13.3K
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K
Induced Pluripotent Stem Cells
4.1K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.1K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
